Highlights of the key data presented at the 58th Annual Meeting of the American Society of Hematology (ASH) on 3 – 6 December 2016 in San Diego, California, USA include:

  • Results from the Myeloma XI trial demonstrating how newly diagnosed patients benefitted from a response-adapted approach to treatment. Patients who switched to a different treatment if they achieved less than a very good partial response after the first 4 – 6 cycles of initial treatment showed significantly improved depth and duration of response
  • Further data from Myeloma XI showing significantly improved progression-free survival in patients who had Revlimid maintenance compared to those who did not, and the applicability of minimal residual disease assessment in older/less fit patients not eligible for autologous high-dose therapy and stem cell transplantation (auto HDT-SCT)
  • Subgroup analyses from the POLLUX and CASTOR trials showing better responses to daratumumab treatment at earlier relapse compared to later stages of the disease and that patients respond equally well regardless of risk status
  • Findings from the largest trial to date of auto HDT-SCT, presented as a late-breaking abstract, showing no difference in progression-free survival regardless of whether patients received Revlimid maintenance or additional treatment such as tandem auto-HDT-SCT or triplet combination consolidation treatment
  • Data from the Phase II STORM trial demonstrating impressive responses in heavily pretreated myeloma patients with the novel drug selinexor, a first-in-class oral selective inhibitor of nuclear export (SINE), including those who were quad- and penta-refractory to treatment (Velcade, carfilzomib, Relimid, pomalidomide and anti-CD38 monoclonal antibody)
  • Results showing that venetoclax, an orally available small molecule inhibitor of Bcl-2 inhibitor, combined with Velcade and dexamethasone showed highly promising efficacy as a treatment for relapsed and/or refractory myeloma patients including those who were refractory to Velcade